2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2171 The DIS3 paradox in multiple myeloma: Biallelic-like DIS3 alterations drive adverse biology at diagnosis but are remodeled during therapy exposure

Alessia D'Anna, Postdoctoral Fellow, Max Fortescue-Poole2, Meghana Ram3, Alison S. Park, N/A4, Kevin Mohammed5, Nayeli Gutierrez Trejo6, Ivan Marazzi7, Adolfo Aleman, PhD8, Santiago Thibaud, MD9, Sundar Jagannath, M.D.10, Samir Parekh, MD11, Ernesto Guccione, PhD12, Alessandro Lagana, PhD13
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 University of California Irvine, Irvine, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background:
In prior mechanistic work, we showed that RNA exosome/Integrator dysfunction impairs productive elongation, induces ERV/LTR derepression, and produces gene-length-dependent transcriptional asymmetry (Torre et al, 2023). Because DIS3 encodes a catalytic component of the RNA exosome and its loss-of-function mutations are recurrent in multiple myeloma (MM), we asked whether DIS3-altered tumors show a related exosome-dysfunction program that varies by allelic state and disease stage. In newly diagnosed MM (NDMM), DIS3 alterations have been previously associated with adverse outcomes (Todoerti et al, 2022). However, in our novel relapsed/refractory MM (rrMM) cohort, DIS3 mutations were unexpectedly associated with favorable progression-free survival (PFS). We therefore asked whether DIS3 biology differs between NDMM and therapy-exposed rrMM.

Methods:
We analyzed N=349 tumor-enriched CD138+ samples from a deeply annotated rrMM cohort with WES, RNA-seq, copy-number alterations, translocations, clinical outcomes, and longitudinal samples in a subset. We evaluated DIS3 status, DIS3-locus copy loss/LOH, aggregate LTR/ERV-associated RNA abundance, gene-length asymmetry, co-expression modules, and clinical associations. We then analyzed MMRF CoMMpass IA24/2025 BM CD138+ WES/RNA-seq samples. CoMMpass PFS was evaluated from first MM-specific treatment. DIS3 allelic state was classified as WT, mutated without DIS3-locus copy loss, or mutated plus DIS3-locus copy loss (biallelic-like). Longitudinal CoMMpass WES compared baseline and later DIS3 variant allele fraction (VAF). TP2+/relapse WES samples were mapped to subsequent therapy lines for exploratory next-line PFS.

Results:
In rrMM, DIS3 mutations were independently associated with longer PFS in multivariable models incorporating CNAs, translocations, driver mutations, tumor mutational burden, genomic scar score, and other genomic risk features (DIS3-mutated n=27; median PFS not reached; HR 0.51; P=0.03). DIS3-altered rrMM showed increased LTR/ERV signal, strongest in biallelic/LOH cases, with a partial gene-length skew in which upregulated coding genes were shorter and often mono- or di-exonic. Single-cell analysis of 3 independent DIS3-mutant tumors supported increased malignant plasma-cell LTR/ERV activity. Co-expression analysis linked DIS3-mutant rrMM to ER quality control/UPR and NF-kB modules. Longitudinal rrMM samples from 6 patients suggested reduction or loss of DIS3-mutant clones after therapy.

In baseline CoMMpass NDMM, simple DIS3 mutation status showed a modest adverse PFS trend (WT n=830; DIS3-mutated n=92; median PFS 1291 vs 1130 days; HR 1.25, P=0.092). Stratification by allelic state showed that this adverse signal was concentrated in biallelic-like cases. DIS3-mutated cases without DIS3-locus copy loss (n=32) did not have inferior PFS versus WT (median PFS 1433 days; HR 1.05, P=0.843), whereas DIS3-mutated cases with DIS3-locus copy loss (n=54) had shorter PFS (median PFS 868 days; HR 1.45, 95% CI 1.06-1.97, P=0.018; global log-rank P=0.06). CoMMpass RNA-seq recapitulated the expected DIS3 exosome-dysfunction phenotype, including LTR-containing TE upregulation and gene-length asymmetry, most evident in biallelic-like tumors.

Longitudinal CoMMpass WES supported therapy-associated depletion of DIS3-mutant burden. Among strict-baseline DIS3-mutated patients with later BM CD138+ WES (n=14), median DIS3 called VAF decreased from 0.496 to 0.288 at the first later sample (median delta VAF -0.122), and 12 of 14 cases decreased or became undetected (paired Wilcoxon P=0.0079). In the relapse/post-TT2L subset (n=10), 8 of 10 decreased or became undetected (median delta VAF -0.087; P=0.058). Exploratory next-line PFS in all available TP2+/relapse CoMMpass samples showed a non-significant favorable trend for DIS3-mutated disease (WT n=121; DIS3-mutated n=8; HR 0.63, P=0.43) but was underpowered.

Conclusions:
DIS3 alterations in MM are stage- and allelic-state-dependent. In NDMM, adverse outcome and canonical exosome-dysfunction programs are enriched in biallelic-like DIS3-mutated tumors. In rrMM, DIS3-mutated disease is associated with favorable PFS, aggregate LTR/ERV activation, stress-response remodeling, and longitudinal depletion of mutant clones. These findings extend RNA exosome biology into MM patients and support a model in which therapy exposure remodels the clinical and molecular consequences of DIS3 alteration.

Alessia D'Anna, Postdoctoral Fellow: No relevant conflicts of interest to declare.